Published in Cancer on July 02, 2013
Addressing overdiagnosis and overtreatment in cancer: a prescription for change. Lancet Oncol (2014) 3.04
Optimization of prostate biopsy: the role of magnetic resonance imaging targeted biopsy in detection, localization and risk assessment. J Urol (2014) 1.55
Active surveillance for the management of localized prostate cancer: Guideline recommendations. Can Urol Assoc J (2015) 1.38
Targeted prostate biopsy in select men for active surveillance: do the Epstein criteria still apply? J Urol (2014) 1.22
Current status of magnetic resonance imaging (MRI) and ultrasonography fusion software platforms for guidance of prostate biopsies. BJU Int (2014) 1.18
Editorial comment. Urology (2015) 1.07
Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: The role of systematic and targeted biopsies. Cancer (2016) 0.98
Optimization of prostate biopsy: review of technique and complications. Urol Clin North Am (2014) 0.93
Multiparametric MRI and targeted prostate biopsy: Improvements in cancer detection, localization, and risk assessment. Cent European J Urol (2016) 0.93
Multiparametric MRI in the PSA screening era. Biomed Res Int (2014) 0.91
Multimodal imaging for improved diagnosis and treatment of cancers. Cancer (2014) 0.90
Multiparametric magnetic resonance imaging and image-guided biopsy to detect seminal vesicle invasion by prostate cancer. J Endourol (2014) 0.89
Natural history of small index lesions suspicious for prostate cancer on multiparametric MRI: recommendations for interval imaging follow-up. Diagn Interv Radiol (2014) 0.89
Standards for prostate biopsy. Curr Opin Urol (2014) 0.88
Prospective Pilot Trial to Evaluate a High Resolution Diffusion-Weighted MRI in Prostate Cancer Patients. EBioMedicine (2016) 0.86
Comparison of Multiparametric MRI Scoring Systems and the Impact on Cancer Detection in Patients Undergoing MR US Fusion Guided Prostate Biopsies. PLoS One (2015) 0.86
Magnetic resonance imaging on disease reclassification among active surveillance candidates with low-risk prostate cancer: a diagnostic meta-analysis. Prostate Cancer Prostatic Dis (2015) 0.85
The role of 3-tesla diffusion-weighted magnetic resonance imaging in selecting prostate cancer patients for active surveillance. Prostate Int (2014) 0.84
Prostate diffusion imaging with distortion correction. Magn Reson Imaging (2015) 0.83
Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools. Am Soc Clin Oncol Educ Book (2016) 0.81
Prostatic ductal adenocarcinoma: an aggressive tumour variant unrecognized on T2 weighted magnetic resonance imaging (MRI). Eur Radiol (2014) 0.80
The role of pathology correlation approach in prostate cancer index lesion detection and quantitative analysis with multiparametric MRI. Acad Radiol (2015) 0.80
Imaging and pathology findings after an initial negative MRI-US fusion-guided and 12-core extended sextant prostate biopsy session. Diagn Interv Radiol (2014) 0.79
Thermoacoustic contrast of prostate cancer due to heating by very high frequency irradiation. Phys Med Biol (2015) 0.79
Prostate Radiotherapy in the Era of Advanced Imaging and Precision Medicine. Prostate Cancer (2016) 0.78
Further reduction of disqualification rates by additional MRI-targeted biopsy with transperineal saturation biopsy compared with standard 12-core systematic biopsies for the selection of prostate cancer patients for active surveillance. Prostate Cancer Prostatic Dis (2016) 0.78
Active surveillance in men with low-risk prostate cancer: current and future challenges. Am J Clin Exp Urol (2013) 0.78
Risk stratification of prostate cancer: integrating multiparametric MRI, nomograms and biomarkers. Future Oncol (2016) 0.78
False positive and false negative diagnoses of prostate cancer at multi-parametric prostate MRI in active surveillance. Insights Imaging (2015) 0.77
Predictive role of free prostate-specific antigen in a prospective active surveillance program (PRIAS). World J Urol (2015) 0.77
Abnormal findings on multiparametric prostate magnetic resonance imaging predict subsequent biopsy upgrade in patients with low risk prostate cancer managed with active surveillance. Abdom Imaging (2014) 0.77
Potential Utility of Novel Biomarkers in Active Surveillance of Low-Risk Prostate Cancer. Biomed Res Int (2015) 0.76
Multiparametric magnetic resonance imaging for prostate cancer improves Gleason score assessment in favorable risk prostate cancer. Pract Radiat Oncol (2015) 0.76
Multiparametric magnetic resonance imaging for prostate cancer: A review and update for urologists. Korean J Urol (2015) 0.76
Active surveillance in intermediate risk prostate cancer: is it safe? Opinion: No. Int Braz J Urol (2016) 0.75
Rule-based versus probabilistic selection for active surveillance using three definitions of insignificant prostate cancer. World J Urol (2015) 0.75
Prostatic intraepithelial neoplasia-like ductal prostatic adenocarcinoma: A case suitable for active surveillance? Urol Ann (2017) 0.75
Recent advances in surgical planning & navigation for tumor biopsy and resection. Quant Imaging Med Surg (2015) 0.75
Gleason score and tumor laterality in radical prostatectomy and transrectal ultrasound-guided biopsy of the prostate: a comparative study. Asian J Androl (2015) 0.75
Active surveillance for prostate cancer: when to recommend delayed intervention. Asian J Androl (2015) 0.75
Predictive values for extracapsular extension in prostate cancer patients with PSA values below 10 ng/mL. Turk J Urol (2014) 0.75
Prostate MRI: a national survey of Urologist's attitudes and perceptions. Int Braz J Urol (2016) 0.75
Current Ability of Multiparametric Prostate Magnetic Resonance Imaging and Targeted Biopsy to Improve the Detection of Prostate Cancer. Urol Pract (2014) 0.75
Comparison of Multiparametric and Biparametric MRI in First Round Cognitive Targeted Prostate Biopsy in Patients with PSA Levels under 10 ng/mL. Yonsei Med J (2017) 0.75
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med (2004) 15.10
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2008) 13.35
Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2011) 11.02
Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. J Natl Cancer Inst (2013) 10.30
Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2006) 9.91
Isolation of amniotic stem cell lines with potential for therapy. Nat Biotechnol (2007) 9.67
Long-term survival of participants in the prostate cancer prevention trial. N Engl J Med (2013) 7.53
Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst (2007) 7.44
Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia (2009) 7.44
Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA (2005) 6.50
A random variance model for detection of differential gene expression in small microarray experiments. Bioinformatics (2003) 6.31
Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med (2015) 6.28
Imaging of angiogenesis: from microscope to clinic. Nat Med (2003) 5.51
Rapid cancer detection by topically spraying a γ-glutamyltranspeptidase-activated fluorescent probe. Sci Transl Med (2011) 4.72
Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2007) 4.64
Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. Eur Urol (2013) 4.64
Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine (Lond) (2008) 4.08
Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med (2007) 3.88
Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays. Clin Cancer Res (2005) 3.79
Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst (2006) 3.62
New strategies for fluorescent probe design in medical diagnostic imaging. Chem Rev (2010) 3.35
Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. Eur Urol (2013) 3.34
Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dubé syndrome. Am J Hum Genet (2005) 3.26
Criteria for the use of omics-based predictors in clinical trials. Nature (2013) 3.15
Selective molecular imaging of viable cancer cells with pH-activatable fluorescence probes. Nat Med (2008) 3.15
Prostate cancer: value of multiparametric MR imaging at 3 T for detection--histopathologic correlation. Radiology (2010) 3.12
Robotic partial nephrectomy for complex renal tumors: surgical technique. Eur Urol (2007) 3.07
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst (2005) 2.99
Racial disparity in renal cell carcinoma patient survival according to demographic and clinical characteristics. Cancer (2012) 2.95
Can magnetic resonance-ultrasound fusion biopsy improve cancer detection in enlarged prostates? J Urol (2013) 2.81
Imaging prostate cancer: a multidisciplinary perspective. Radiology (2007) 2.79
Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat Med (2011) 2.76
Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci U S A (2007) 2.71
Utility of multiparametric magnetic resonance imaging suspicion levels for detecting prostate cancer. J Urol (2013) 2.62
Overview of dynamic contrast-enhanced MRI in prostate cancer diagnosis and management. AJR Am J Roentgenol (2012) 2.59
Correlation of magnetic resonance imaging tumor volume with histopathology. J Urol (2012) 2.55
Image-guided tumor ablation: proposal for standardization of terms and reporting criteria. Radiology (2003) 2.53
In vivo molecular imaging of cancer with a quenching near-infrared fluorescent probe using conjugates of monoclonal antibodies and indocyanine green. Cancer Res (2009) 2.51
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol (2012) 2.51
Laparoendoscopic single-site surgery in urology: worldwide multi-institutional analysis of 1076 cases. Eur Urol (2011) 2.46
Simultaneous multicolor imaging of five different lymphatic basins using quantum dots. Nano Lett (2007) 2.46
Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention. Cancer Prev Res (Phila) (2008) 2.43
11C-Acetate PET/CT in localized prostate cancer: a study with MRI and histopathologic correlation. J Nucl Med (2012) 2.42
Real-time MRI-TRUS fusion for guidance of targeted prostate biopsies. Comput Aided Surg (2008) 2.39
Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images? Radiology (2010) 2.38
Prostate cancer: can multiparametric MR imaging help identify patients who are candidates for active surveillance? Radiology (2013) 2.35
Characteristics of congenital hepatic fibrosis in a large cohort of patients with autosomal recessive polycystic kidney disease. Gastroenterology (2012) 2.33
The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease. J Urol (2004) 2.32
Image-guided tumor ablation: standardization of terminology and reporting criteria. J Vasc Interv Radiol (2009) 2.29
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. Cancer Res (2013) 2.27
Multiparametric magnetic resonance imaging outperforms the Prostate Cancer Prevention Trial risk calculator in predicting clinically significant prostate cancer. Cancer (2014) 2.27
Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors. Blood (2004) 2.27
Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res (2006) 2.24
Toxicity of organic fluorophores used in molecular imaging: literature review. Mol Imaging (2009) 2.21
Overall survival advantage with partial nephrectomy: a bias of observational data? Cancer (2013) 2.21
MRI of tumor angiogenesis. J Magn Reson Imaging (2007) 2.19